Clinical Trial Search

Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants

Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants

Primary: Derived Parasite Reduction Rate at 24 Hours (PPR24) — 1.38; 1.56; 1.71; 1.63 Log10 parasites/24h — p=0.01

Primary: Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 11; 13; 15; 14 Participants

Primary: Infection Rate — 5; 6; 3; 0 Participants

Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat…

Primary: Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs — 9; 0; 1 Participants

Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio

Primary: Time to Parasite Clearance — 23.63; 44.97; 48.75 Hours

Primary: Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 — 46; 45; 47; 47…

Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence

Primary: Time to Parasitemia Since Negative Blood Smear After Treatment — 62.0; 60.0; NA; NA days

Primary: Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 99.2; 98.1 percentage of subjects — p=0.106

Primary: Crude Adequate Clinical and Parasitological Response (ACPR) — 90; 100 percentage of participants

Primary: Crude Cure Rate on Day 14 — 217; 209; 75; 73 Participants

Primary: Absence of Malaria Parasites in Blood. — 73 Participants

Primary: Emax — 0.201 Maximum clearance rate (1/hour)

Primary: The Activity of Single Oral Doses of MMV533 (Name of Investigational Medicinal Product) on Clearance of Plasmodium — 42.17; 158.03; 187.57 PRR48=parasite reduction ratio…

Primary: Early Treatment Failure (ETF) — 0; 0 participants

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Polymerase Chain Reaction (PCR) Corrected Adequate Clinical and Parasitological Response (ACPR) — 96.43; 96.67 Percentage of participants

Primary: Prevalence of Placental Malaria — 49; 30; 26 Participants

Primary: 28-day Cure Rate — 63.67 Percentage of participants

Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28) — 80.8; 90.3; 90.9…

Primary: Number of Participants Who Deliver With a Composite Adverse Birth Outcome — 60; 54 Participants

Primary: PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28 — 99.5; 99.2 percentage of subjects — p=0.578

Primary: PCR-Corrected ACPR at Day 28 — 95; 99; 99 percentage of subjects

Primary: Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community…

Primary: Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) - Cohorts 1 and 2 Pooled — 99.0; 99.0 Percentage of participants

Primary: PCR-adjusted ACPR at Day 28 in the PP Population (All Patients) — 70.8; 68.4; 78.6 % ACPR PCR-adjusted